Kyverna Therapeutics (KYTX) grants CFO Martini 325,000 stock options

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Martini received a grant of stock options covering 325,000 shares of common stock. The options have an exercise price of $8.54 per share and expire on May 18, 2036. One quarter of the option grant vests on May 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continuous service. Following this compensation-related award, Martini holds 325,000 derivative securities directly, with no open-market purchases or sales reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Martini Gregory S.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	325,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 325,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 325,000 options Exercise price: $8.54 per share Expiration date: May 18, 2036 +2 more

5 metrics

Options granted 325,000 options Stock Option (right to buy) grant to CFO on May 18, 2026

Exercise price $8.54 per share Exercise price for CFO stock option grant

Expiration date May 18, 2036 Option term end for CFO grant

Underlying shares 325,000 shares Common stock underlying the granted options

Post-grant derivative holdings 325,000 options Total derivative securities held directly after transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 8.5400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-18T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"1/4th of the shares subject to the option shall vest on May 18, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martini Gregory S.

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 200

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.54	05/18/2026		A		325,000		(1)	05/18/2036	Common Stock	325,000	$0	325,000	D

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on May 18, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

	/s/ Samantha H. Eldredge, as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kyverna Therapeutics (KYTX) disclose in this Form 4 for its CFO?

Kyverna reported that CFO Gregory S. Martini received a grant of stock options for 325,000 shares of common stock at a $8.54 exercise price as part of his compensation, with future vesting based on continued service.

How many Kyverna (KYTX) stock options were granted to CFO Gregory S. Martini?

Gregory S. Martini was granted options on 325,000 Kyverna common shares. These derivative securities give him the right to buy shares at a fixed $8.54 exercise price if and when the options vest over time.

What is the exercise price and expiration date of the Kyverna (KYTX) CFO’s options?

The stock options granted to Kyverna’s CFO carry an exercise price of $8.54 per share and expire on May 18, 2036. This long-dated term allows potential exercise well into the future if vesting and service conditions are satisfied.

How do the Kyverna (KYTX) CFO’s stock options vest over time?

One quarter of the granted options vest on May 18, 2027. The remaining three quarters vest in equal monthly installments over the next 36 months, conditioned on Gregory S. Martini’s continuous service through each vesting date.

Did the Kyverna (KYTX) Form 4 show any open-market buying or selling by the CFO?

The Form 4 shows only a compensation-related grant of stock options, coded as an acquisition (A), with no open-market purchases or sales. After this award, the CFO directly holds 325,000 derivative securities tied to Kyverna common stock.